Compare Church & Dwight Co., Inc. (CHD) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Ginkgo Bioworks Holdings Inc — how do they compare? Church & Dwight Co., Inc. trades at $97.03 (market cap $22.61B), while Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M). The key difference: Church & Dwight Co., Inc. is far larger — about 38.3× Ginkgo Bioworks Holdings Inc's market cap, and Church & Dwight Co., Inc. pays a 1.29% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| CHD | DNA | |
|---|---|---|
Market Cap | $22.61B | $590.53M |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $16.14 |
52-Week Low | $81.60 | $5.48 |
Enterprise Value | $24.31B | $627.78M |
Dividend Yield | 1.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $97.16, up 0.83% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with 11.81% net margins and consistent organic growth, supported by strategic acquisitions like Miss Mouth's brand. Analyst consensus remains positive with a $105.60 price target, though cash flow trends show recent negative net flows.
CHD presents a balanced opportunity with solid brand execution and margin expansion potential, offset by cash flow volatility and competitive pressures. The stock's premium valuation requires sustained earnings growth to justify upside, with Q2 2026 earnings on July 31 as a key catalyst.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
